Post-transplant lymphoproliferative disorder (PTLD) is the name for types of lymphoma that sometimes develop in people who have had a transplant. It can affect people who are taking medicines to suppress their immune system. This study is being done to study whether treating PTLD with a combination of the drugs tafasitamab and rituximab is more effective than rituximab alone - the current standard of care treatment for this disease.

The study is researching an experimental drug called odronextamab. The study is for patients with previously untreated follicular lymphoma (a type of non-Hodgkin lymphoma). In this study, we want to find out more about how safe and tolerable the study drug is. We will also compare how well the study drug orks compared to rituximab and chemotherapy (the current standard of care for NHL).

The purpose of this research study is to collect blood from patients with B-cell lymphoma who are scheduled to receive lymphodepletion chemotherapy and CAR-T cells. Research on blood samples can help in understanding how the body and cancer respond to these treatments.

This is a prospective study that will look for the kinetics of circulating tumor DNA (ctDNA) in patients with hematologic and pediatric cancer before and after undergoing standard of care treatment regimens where radiation therapy is a treatment.

Have you been diagnosed with CD30 negative peripheral T-cell lymphoma? If so, you may be able to take part in a research study that will look at the safety of adding the new study drug duvelisib, or the new study drug CC-486, to the standard chemotherapy treatment for your disease. Please contact us with questions about eligibility, or if you wish to know more.

Do you have head and neck cancer or soft tissue sarcoma? Are you planning to have surgery to remove your tumor? You may be able to participate in a research study to determine which therapies may be best for future patients. Compensation provided.

Have you been diagnosed with diffuse large B-cell lymphoma? Have you already received treament for your cancer, but it either came back or did not improve? Then you may be eligible for a study to look at the safety and effectiveness of the combination of treatments with rituximab, gemcitabine, dexamethasone, cisplatin and the study drug polatuzumab vedotin

Have you been diagnosed with Hodgkin's Lymphoma. Are you looking for options to treat cancer ?If so, you may be able to take part in a research study looking at the safety of giving a new drug called ATLCAR.CD30.CCR4

Have you been recently diagnosed with Diffuse Large B Cell Lymphoma? Are you over 75 years of age? If so, you may be able to take part in a research study looking at the safety of giving a new study drug CC-486 (oral azacitidine) in addition to the standard chemotherapy drug combination used to treat this disease.

Do you have cancer? Are you about to start immunotherapy? You may be able to participate in a research study to help answer many questions that still exist about immunotherapy like - Who is more likely to get side effects? What treatments will help control the side effects but let patients continue their cancer treatment? What factors can affect the type of side effects patients have (type of cancer or immunotherapy? previous chemo or radiation? existing autoimmune diseases?, etc.) and more.